Authors:
Johnson, KP
Brooks, BR
Ford, CC
Goodman, A
Guarnaccia, J
Lisak, RP
Myers, LW
Panitch, HS
Pruitt, A
Rose, JW
Kachuck, N
Wolinsky, JS
Citation: Kp. Johnson et al., Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years, MULT SCLER, 6(4), 2000, pp. 255-266
Authors:
Vickrey, BG
Edmonds, ZV
Shatin, D
Shapiro, MF
Delrahim, S
Belin, TR
Ellison, GW
Myers, LW
Citation: Bg. Vickrey et al., General neurologist and subspecialist care for multiple sclerosis - Patients' perceptions, NEUROLOGY, 53(6), 1999, pp. 1190-1197
Citation: Jm. Bronstein et al., A humoral response to oligodendrocyte-specific protein in MS - A potentialmolecular mimic, NEUROLOGY, 53(1), 1999, pp. 154-161
Citation: Lw. Myers et al., Selection of patients for therapeutic clinical trials in multiple sclerosis, FRONTIERS IN MULTIPLE SCLEROSIS, VOL 2, 1999, pp. 151-160
Authors:
Ford, CC
Brooks, BR
Johnson, KP
Lisak, RP
Myers, LW
Panitch, HS
Rose, JW
Schiffer, RB
Vollmer, T
Weiner, LP
Wolinsky, JS
Citation: Cc. Ford et al., Sustained efficacy of glatiramer acetate for injection in a 5+ year trial of relapsing remitting MS, MULT SCLER, 4(6), 1998, pp. 521-521